Fluvastatin: Brands, Price & Uses in Bangladesh

Fluvastatin is a statin (HMG-CoA reductase inhibitor) indicated for the management of dyslipidemia and for reducing cardiovascular risk. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Primary hyperlipidemia and mixed dyslipidemia: Fluvastatin is indicated, as an adjunct to diet, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults with primary hypercholesterolemia (Fredrickson type IIa) and mixed dyslipidemia (type IIb).
• Slowing progression of coronary atherosclerosis: Fluvastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy that also lowers total-C and LDL-C.
• Reduction of risk of coronary revascularization procedures: Fluvastatin is indicated to reduce the risk of undergoing coronary revascularization procedures in patients with coronary heart disease.
• Heterozygous familial hypercholesterolemia (pediatric, ≥10 years): Fluvastatin is indicated, as an adjunct to diet, to reduce LDL-C in adolescents with heterozygous familial hypercholesterolemia who require the 80 mg dose.

Adjunct-therapy note

Fluvastatin is always intended to be used together with diet, exercise, and weight management as first-line measures; it is an adjunct to, not a replacement for, lifestyle modification.

Off-label use

Fluvastatin is occasionally used off-label for lipid management in select post-transplant patients (owing to fewer CYP3A4-mediated interactions with immunosuppressants than some other statins), but this is not an FDA-approved indication and should only be undertaken under specialist supervision.

Dosage of Fluvastatin should be individualized according to the indication, baseline LDL-C, treatment goal, and patient response, with periodic lipid monitoring (e.g., at 4-week intervals) and dose adjustment as needed.

Renal impairment

No dosage adjustment is generally required in mild-to-moderate renal impairment. Fluvastatin should be used with caution and at the lowest effective dose in patients with severe renal impairment, with close monitoring for myopathy.

Hepatic impairment

Fluvastatin is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases (see Contraindications). Liver function should be assessed before starting therapy and if symptoms suggestive of hepatotoxicity occur.

The most commonly reported adverse effects of Fluvastatin (generally mild) include:

• Headache
• Dyspepsia and abdominal discomfort
• Nausea
• Influenza-like symptoms, sinusitis, bronchitis
• Myalgia (mild muscle aches)
• Insomnia

Less common but more serious effects — including myopathy/rhabdomyolysis, liver enzyme elevation, and immune-mediated necrotizing myopathy — are discussed in detail under Precautions and Warnings; patients experiencing unexplained muscle pain, weakness, or dark urine should seek medical attention promptly.